Sun Pharmaceutical Industries’ arm gets US FDA’s nod for generic Cardizem CD

31 Oct 2011 Evaluate

Sun Pharmaceutical Industries’ subsidiary has been granted a tentative approval from United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market a generic version of Cardizem CD, Diltiazem HCL extended release capsules. These Diltiazem HCL extended release capsules are equivalent to Valeant international’s, Cardizem CD, 120mg, 180mg, 240mg, 300mg and 360mg. Annual sale in the US for these strengths is about $300 million.

Diltiazem HCL extended release capsules are indicated in the treatment of hypertension, for the management of chronic stable angina and angina due to coronary artery spasm.

Sun Pharmaceutical Industries manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.

Sun Pharma Inds. Share Price

1722.05 2.45 (0.14%)
31-Dec-2025 10:42 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1722.05
Dr. Reddys Lab 1267.50
Cipla 1498.00
Zydus Lifesciences 913.20
Lupin 2086.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×